D'Incecco A - Search Results

1

Gefitinib for non-small-cell lung cancer treatment.

D'Incecco A, Cappuzzo F. D'Incecco A, et al. Expert Opin Drug Saf. 2011 Nov;10(6):987-96. doi: 10.1517/14740338.2011.617738. Epub 2011 Sep 12. Expert Opin Drug Saf. 2011. PMID: 21905963 Review.

2

Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study.

Tibaldi C, Mazzoni E, Arcabasso G, D'Incecco A, Antonuzzo A, Menconi G, Falcone A. Tibaldi C, et al. Clin Lung Cancer. 2009 Jan;10(1):53-7. doi: 10.3816/CLC.2009.n.008. Clin Lung Cancer. 2009. PMID: 19289373 Clinical Trial.

3

Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.

Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C. Giovannetti E, et al. Mol Cancer Ther. 2010 Mar;9(3):581-93. doi: 10.1158/1535-7163.MCT-09-0665. Epub 2010 Feb 16. Mol Cancer Ther. 2010. PMID: 20159991 Free article.

4

Second-line treatment for non-small-cell lung cancer: one size does not fit all.

Caponi S, Vasile E, Ginocchi L, Tibaldi C, Borghi F, D'Incecco A, Lucchesi M, Caparello C, Andreuccetti M, Falcone A. Caponi S, et al. Clin Lung Cancer. 2010 Sep 1;11(5):320-7. doi: 10.3816/CLC.2010.n.040. Clin Lung Cancer. 2010. PMID: 20837457 Review.

5

Consequences of targeted treatments for second-line therapy.

De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, Cappuzzo F. De Maio E, et al. Ann Oncol. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. Ann Oncol. 2010. PMID: 20943621 Free article. Review.

6

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.

Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ. Lemos C, et al. Pharmacogenomics. 2011 Feb;12(2):159-70. doi: 10.2217/pgs.10.172. Pharmacogenomics. 2011. PMID: 21332310 Free PMC article.

7

Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.

Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D'Incecco A, Loosekoot N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzoni A, Peters GJ. Tibaldi C, et al. Ann Oncol. 2012 Mar;23(3):670-677. doi: 10.1093/annonc/mdr280. Epub 2011 Jun 7. Ann Oncol. 2012. PMID: 21652582 Free article.

8

First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.

Tibaldi C, Camerini A, D'Incecco A, Vasile E, Fabbri A, Amoroso D, Cappuzzo F. Tibaldi C, et al. J Cancer Res Clin Oncol. 2012 Dec;138(12):2003-8. doi: 10.1007/s00432-012-1280-5. Epub 2012 Jul 6. J Cancer Res Clin Oncol. 2012. PMID: 22767317 Clinical Trial.

9

Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.

Landi L, Minuti G, D'Incecco A, Cappuzzo F. Landi L, et al. Curr Opin Oncol. 2013 Mar;25(2):130-6. doi: 10.1097/CCO.0b013e32835daf37. Curr Opin Oncol. 2013. PMID: 23385860 Review.

10

Rare mutations in non-small-cell lung cancer.

D'Arcangelo M, D'Incecco A, Cappuzzo F. D'Arcangelo M, et al. Future Oncol. 2013 May;9(5):699-711. doi: 10.2217/fon.13.16. Future Oncol. 2013. PMID: 23647298 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters